PeptidePlaza
The Free Peptide Reference

Insulin Zinc

From PeptidePlaza, the free peptide reference · Entry #1218 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Insulin Zinc (also known as Caninsulin, Monotard, Zinc-insulinum, Insulin lente) is a metabolic research peptide. Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.

Insulin Zinc, also known as Insulin, Protamine Zinc, is an insulin receptor agonist. It functions by binding to and activating insulin receptors, mimicking the action of endogenous insulin. This compound is FDA-approved, indicating its established use in medical treatments. Research into Insulin Zinc includes studies on its suspension formulations and its role in managing conditions related to insulin resistance. The literature also explores its connection to zinc status and glycoxidative stress in individuals with type 2 diabetes mellitus.

1 Mechanism of action

Insulin receptor agonist (agonist)

Primary targets: Insulin receptor

2 Chemical and physical properties

CAS number53027-39-7
Molar mass5873 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsInsulin receptor

3 Research studies (8)

  1. INSULIN zinc suspensions
    British medical journal (1953)
  2. Formulation of protein-loaded nanoparticles via freeze-drying
    Drug delivery and translational research (2024)
  3. [Insulin-zinc suspensions]
    El Dia medico (1954)
  4. INSULIN zinc suspensions
    Nutrition reviews (1956)
  5. Zinc status, insulin resistance and glycoxidative stress in elderly subjects with type 2 diabetes mellitus
    Experimental and therapeutic medicine (2021)
  6. The insulin-zinc suspensions
    Lancet (London, England) (1954)
  7. Functionality of receptor targeted zinc-insulin quantum clusters in skin tissue augmentation and bioimaging
    Journal of drug targeting (2021)
  8. Zinc stimulates glucose oxidation and glycemic control by modulating the insulin signaling pathway in human and mouse skeletal muscle cell lines
    PloS one (2018)

4 Safety and risk profile

4.1 Regulatory status

Insulin Zinc is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

5 Frequently asked questions

What is Insulin Zinc?
Insulin Zinc is an insulin receptor agonist. It is also known by the name Insulin, Protamine Zinc. This compound is FDA-approved for medical use.
How does Insulin Zinc work?
Insulin Zinc functions as an insulin receptor agonist. This means it binds to and activates insulin receptors, thereby mimicking the effects of natural insulin in the body.
Is Insulin Zinc FDA approved?
Yes, Insulin Zinc is an FDA-approved compound, indicating it has met regulatory standards for medical use.
What has Insulin Zinc been studied for?
Insulin Zinc has been studied in various contexts, including its suspension formulations. Research also explores its relationship with zinc status, insulin resistance, and glycoxidative stress, particularly in elderly subjects with type 2 diabetes mellitus.

6 References

  1. Insulin Zinc — compound summary PubChem. View source
  2. Insulin Zinc — molecule record ChEMBL. View source
  3. Insulin Zinc — published literature (105 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Insulin Zinc.

Insulin Glargineapproved

Also targets Insulin receptor

Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.

Insulin Aspartapproved

Also targets Insulin receptor

Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.

Insulin Lisproapproved

Also targets Insulin receptor

Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.

Insulin Degludecapproved

Also targets Insulin receptor

Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.

Insulin Detemirapproved

Also targets Insulin receptor

Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.

Insulin Zinc, Extendedmetabolic

Also targets Insulin receptor

Insulin Zinc, Extended is an insulin receptor agonist currently in Phase 2 clinical trials.

7 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.